J
Julia Meissner
Researcher at Heidelberg University
Publications - 52
Citations - 2187
Julia Meissner is an academic researcher from Heidelberg University. The author has contributed to research in topics: Procarbazine & Dacarbazine. The author has an hindex of 20, co-authored 52 publications receiving 1468 citations. Previous affiliations of Julia Meissner include Boston University & University Hospital Heidelberg.
Papers
More filters
Journal ArticleDOI
Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial
Bastian von Tresckow,Annette Plütschow,Michael Fuchs,Beate Klimm,Jana Markova,Andreas Lohri,Zdenek Kral,Richard Greil,Max S. Topp,Julia Meissner,Josée M. Zijlstra,Martin Soekler,Harald Stein,Hans Theodor Eich,Rolf P. Mueller,Volker Diehl,Peter Borchmann,Andreas Engert +17 more
TL;DR: Intensified chemotherapy with two cycles of BEACOPP escalated followed by three cycles of ABVD followed by IFRT significantly improves tumor control in patients with early unfavorable HL.
Journal ArticleDOI
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
Peter Borchmann,Helen Goergen,Carsten Kobe,Andreas Lohri,Richard Greil,Dennis A. Eichenauer,Josée M. Zijlstra,Jana Markova,Julia Meissner,Michaela Feuring-Buske,Andreas Hüttmann,Judith Dierlamm,Martin Soekler,Hans Joachim Beck,Wolfgang Willenbacher,Wolf-Dieter Ludwig,Thomas Pabst,Max S. Topp,Felicitas Hitz,Martin Bentz,Ulrich Keller,Dagmar Kühnhardt,Helmut Ostermann,Norbert Schmitz,Bernd Hertenstein,Walter E. Aulitzky,Georg Maschmeyer,Tom Vieler,Hans Theodor Eich,Christian Baues,Harald Stein,Michael Fuchs,Georg Kuhnert,Volker Diehl,Markus Dietlein,Andreas Engert +35 more
TL;DR: This open-label, randomised, parallel-group phase 3 trial investigated whether metabolic response determined by PET after two cycles of standard regimen eBEACOPP (PET-2) would allow adaption of treatment intensity, increasing it for PET-2-positive patients and reducing it forPET- 2-negative patients and showed non-inferiority in the 5-year progression-free survival estimates.
Journal ArticleDOI
Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†
Matteo Lambertini,Fedro A. Peccatori,Isabelle Demeestere,Frédéric Amant,Christine Wyns,Jan-Bernd Stukenborg,Shani Paluch-Shimon,Michael J. Halaska,Catherine Uzan,Julia Meissner,M. von Wolff,Richard A. Anderson,Karin Jordan +12 more
Journal ArticleDOI
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
Karolin Behringer,Helen Goergen,Felicitas Hitz,Josée M. Zijlstra,Richard Greil,Jana Markova,Stephanie Sasse,Michael Fuchs,Max S. Topp,Martin Soekler,Stephan Mathas,Julia Meissner,Martin Wilhelm,Peter Koch,Hans-Walter Lindemann,Enrico Schalk,Robert Semrau,Jan Kriz,Tom Vieler,Martin Bentz,Elisabeth Lange,Rolf Mahlberg,Andre Hassler,Martin Vogelhuber,Dennis Hahn,Jörg Mezger,Stefan W. Krause,Nicole Skoetz,Boris Böll,Bastian von Tresckow,Volker Diehl,Michael Hallek,Peter Borchmann,Harald Stein,Hans Theodor Eich,Andreas Engert +35 more
TL;DR: Non-inferiority of the experimental variants compared with ABVD in terms of freedom from treatment failure (FFTF) is shown by excluding a difference of 6% after 5 years corresponding to a hazard ratio (HR) of 1.72, via a 95% CI.
Journal ArticleDOI
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
Michael Fuchs,Helen Goergen,Carsten Kobe,Georg Kuhnert,Andreas Lohri,Richard Greil,Stephanie Sasse,Max S. Topp,Erhardt Schäfer,Bernd Hertenstein,Martin Soekler,Martin Vogelhuber,Josee M. Zijlstra,Ulrich Keller,Stefan W. Krause,Martin Wilhelm,Georg Maschmeyer,Julia Thiemer,Ulrich Dührsen,Julia Meissner,Andreas Viardot,Hans Theodor Eich,Christian Baues,Volker Diehl,Andreas Rosenwald,Bastian von Tresckow,Markus Dietlein,Peter Borchmann,Andreas Engert +28 more
TL;DR: In early-stage favorable HL, a positive PET after two cycles ABVD indicates a high risk for treatment failure, particularly when a Deauville score of 4 is used as a cutoff for positivity in PET-2-positive patients.